| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Medical Officer | Chief Medical Officer
1 company
Paul K. Audhya is Chief Medical Officer at KALV. Paul K. Audhya's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $3.8M at current prices.
Our model assigns Paul K. Audhya a below-average insider score of 44/100, based on 22 past trades. Over a 12-month horizon, 11.8% of those trades were profitable, with an average 12-month return of -38.1%.
The KALV filings lean toward selling, a net 103,890 shares.
Paul K. Audhya has 27 Form 4 filings on record from May 2021 to April 2026, all as Chief Medical Officer at KalVista Pharmaceuticals (KALV), 2021–2026.
The 54 reported transactions were 24 option exercises, 23 open-market sales and 7 option or other derivative awards.
Counted by filing, the open-market trades come to no purchases and 23 sales worth about $1.2M.
The largest open-market sale was 14,295 shares of KALV at an average $14.12 on February 20, 2024, about $202K. Twelve months later KALV was down 22%.
None of the 20 sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr 17, 2026 | KALV Kalvista Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 2,686 | $20.22 | $54,300.98 | -1.8% | - | - | |
| Nov 24, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 5,296 | $13.45 | $71,236.50 | -3.9% | +16.5% | - | |
| Nov 18, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 3,075 | $14.48 | $44,524.46 | -2.4% | +5.0% | - | |
| Aug 25, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 2,336 | $13.42 | $31,349.12 | -1.9% | +2.8% | - | |
| Aug 22, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 2,942 | $13.22 | $38,901.48 | -2.4% | -2.9% | - | |
| Aug 18, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 2,939 | $13.19 | $38,756.59 | -2.5% | +11.4% | - | |
| May 23, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 2,146 | $11.31 | $24,271.69 | -1.9% | +13.0% | +133.6% | |
| May 22, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 2,689 | $11.88 | $31,933.22 | -2.4% | +13.0% | +134.6% | |
| May 19, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 2,776 | $11.84 | $32,875.61 | -2.5% | +10.5% | +121.8% | |
| Feb 24, 2025 | KALV Kalvista Pharmaceuticals, Inc. | Chief Medical Officer | Sale+OE | 2,394 | $10.02 | $23,987.88 | -2.3% | +8.3% | +52.2% |